FierceBiotech3d
Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...
Maze Therapeutics targets up to $728 million valuation in US IPO
(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...